Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy argenx stock

Own argenx stock in just a few minutes.

Fact checked

argenx SE is a biotechnology business based in the US. argenx shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx employs 186 staff and has a market cap (total outstanding shares value) of USD$14.4 billion.

How to buy shares in argenx

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for argenx. Find the stock by name or ticker symbol: ARGX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until argenx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of argenx, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of argenx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

argenx share price

Use our graph to track the performance of ARGX stocks over time.

argenx shares at a glance

Information last updated 2020-12-26.
52-week rangeUSD$103.75 - USD$312.06
50-day moving average USD$280.3926
200-day moving average USD$252.5062
Wall St. target priceUSD$293.62
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.725

Buy argenx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy argenx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

argenx financials

Gross profit TTM USD$-115,081,000
Return on assets TTM -13.5%
Return on equity TTM 0%
Profit margin 0%
Book value $11.953
Market capitalisation USD$14.4 billion

TTM: trailing 12 months

Shorting argenx shares

There are currently 1.1 million argenx shares held short by investors – that's known as argenx's "short interest". This figure is 2.4% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting argenx shares can be evaluated.

argenx's "short interest ratio" (SIR)

argenx's "short interest ratio" (SIR) is the quantity of argenx shares currently shorted divided by the average quantity of argenx shares traded daily (recently around 161007.90960452). argenx's SIR currently stands at 7.08. In other words for every 100,000 argenx shares traded daily on the market, roughly 7080 shares are currently held short.

However argenx's short interest can also be evaluated against the total number of argenx shares, or, against the total number of tradable argenx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case argenx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 argenx shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable argenx shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against argenx.

Find out more about how you can short argenx stock.

argenx share dividends

We're not expecting argenx to pay a dividend over the next 12 months.

argenx share price volatility

Over the last 12 months, argenx's shares have ranged in value from as little as $103.75 up to $312.06. A popular way to gauge a stock's volatility is its "beta".

ARGX.US volatility(beta: 0.87)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx's is 0.8693. This would suggest that argenx's shares are less volatile than average (for this exchange).

argenx overview

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site